Best in Biotech 26 Jun 2023 Five animal health companies you should know about …Parvovirus Monoclonal Antibody, which targets canine parvovirus (CPV); and Seresto for Dogs, for preventing ticks and fleas. Meanwhile, for farm animals, the company supports the prevention, control and treatment of… June 26, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
More News! 22 Nov 2018 First Drug for Rare Inflammation Syndrome Approved by FDA …antibody drug, emapalumab, is approved to treat primary hemophagocytic lymphohistiocytosis. This condition is a rare, often fatal syndrome in which the immune system produces too many activated immune cells, as… November 22, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 20 Sep 2017 A Peek Inside Europe’s Best Incubator: A Conversation with Babraham’s Chief Executive …field, Cambridge Antibody Technology, grew out of Babraham. Bicycle Therapeutics, Kymab, and Crescendo Biologics all count with former CAT employees and are now following in its footsteps to improve antibody-based… September 20, 2017 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 7 Feb 2017 British Synbio’s Llama Antibodies recruited for Cancer T-Cell Therapy Isogenica has licensed its synthetic llama antibody library to Maverick Therapeutics, which develops cancer T-cell therapies designed to reduce side effects. Isogenica is a synthetic biology company near Cambridge that… February 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2017 This British Biotech is buying its way into the Crowded NASH Space …the company is in-licensing a fully human monoclonal antibody from Novimmune, in Switzerland. No details on the size of the deal have been disclosed. The drug candidate in question, NI-1201,… January 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Incyte to acquire Medicxi-backed Villaris Therapeutics to tackle vitiligo Incyte has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development of novel antibody therapeutics for vitiligo. The deal… October 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 26 Nov 2019 Rare Inflammatory Disease Drug Beats Immunosuppressants in Phase III …disease than current treatments in a phase III trial. The drug avacopan was trialed in 331 patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. This life-threatening condition is also known as ANCA… November 26, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Dec 2019 €48M Series B Fuels Immunotherapies for Cancer and Autoimmune Diseases …use the money to fund the first phase I trial for its lead antibody immunotherapy for the treatment of various kinds of solid and liquid tumors. The trial is expected… December 4, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2020 SynOx Joins Wave of Biotechs Attacking Solid Tumor ‘Comfort Zone’ …Celleron Therapeutics last week with a huge Series A round of €37M. The fledgling company is developing an antibody drug that Celleron licensed from Roche in August to treat a… November 23, 2020 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 May 2020 Update: ADC Therapeutics’ IPO Hits Above Target with €215M …large B-cell lymphoma, and ultimately bring the drug to the US market. Lausanne-based ADC Therapeutics specializes in the development of antibody-drug conjugates, in which an antibody is attached to a… May 15, 2020 - 4 minutesmins - By Laura Cowen Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2023 Sanofi drug reduces disease activity in relapsing MS New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a… June 1, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 30 Oct 2024 Could next-generation “switchable” CAR-T cells help improve the safety and efficacy of CAR-T therapies? …different methods can be used, but generally speaking, it involves giving the patient a separate administration of another substance – whether that be an existing drug or a novel antibody,… October 30, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email